MEDICIS PHARMACEUTICAL CORPORATION Patent applications |
Patent application number | Title | Published |
20140323516 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 10-30-2014 |
20140274982 | TOPICAL COMPOSITIONS OF FLUNISOLIDE AND METHODS OF TREATMENT - Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide. | 09-18-2014 |
20140206735 | HIGH DOSAGE TOPICAL METRONIDAZOLE AQUEOUS-BASED GEL FORMULATIONS AND THEIR USE TO TREAT ROSACEA - The present disclosure provides aqueous-based gel formulations of metronidazole useful for a variety of purposes, including topical application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with rosacea. | 07-24-2014 |
20140187575 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 07-03-2014 |
20140045911 | Phenoxy-Pyrrolidine Derivative and Its Use and Compositions - The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound. | 02-13-2014 |
20130253003 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 09-26-2013 |
20130210855 | 2 X 2 X 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 08-15-2013 |
20130190715 | COMBINATION THERAPY WITH LOW DOSAGE STRENGTH IMIQUIMOD AND PHOTODYNAMIC THERAPY TO TREAT ACTINIC KERATOSIS - This disclosure is directed to the use of complementary or combination photodynamic therapy and topical therapy with a lower dosage strength imiquimod formulation for treating actinic keratosis. | 07-25-2013 |
20130178446 | METHOD FOR DECREASING SEBUM PRODUCTION - The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin. | 07-11-2013 |
20130149341 | METHODS OF IMPROVING SKIN QUALITY - Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs. | 06-13-2013 |
20130018031 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS - Aminoalkylpyrimidine derivatives of formula I, wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H | 01-17-2013 |
20130005787 | HIGH DOSAGE MUCOADHESIVE METRONIDAZOLE AQUEOUS-BASED GEL FORMULATIONS AND THEIR USE TO TREAT BACTERIAL VAGINOSIS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis. | 01-03-2013 |
20130005785 | METHODS OF TREATING BACTERIAL VAGINOSIS WITH AQUEOUS-BASED METRONIDAZOLE GEL FORMULATIONS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis. | 01-03-2013 |
20120329835 | USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS - Compounds of the formula (1) are disclosed and are suitable for the treatment of seborrheic dermatitis. | 12-27-2012 |
20120329825 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120329824 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120329823 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120289538 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 11-15-2012 |
20120289537 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 11-15-2012 |
20120289490 | COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY - The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70. | 11-15-2012 |
20120283286 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 11-08-2012 |
20120277280 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS - The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound. | 11-01-2012 |
20120264778 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 10-18-2012 |
20120238913 | METHODS OF EVALUATING NORMALCY OF LIPS AND SAFETY OF LIP TREATMENTS - This disclosure relates to evaluating and objectively determining the relative normalcy of a human patient's lips, whether before or after a lip treatment, or independent from any lip treatment. The normalcy of a patient's lips is evaluated by examining a number of indicia and comparing the results to corresponding lip scales or reference descriptions. The normalcy may be evaluated before and after a lip treatment to determine the safety of the lip treatment. | 09-20-2012 |
20120115954 | Aqueous retinoid and benzoyl peroxide gel - Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid. | 05-10-2012 |
20120093892 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 04-19-2012 |
20120083507 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 04-05-2012 |
20120082710 | METHODS AND COMPOSITIONS FOR TREATING ACNE - A method for treating acne on the skin. The method has the steps of (a) providing an drapeable or flexible porous article impregnated with an aqueous cleansing composition having a carrier, benzoyl peroxide, and one or more cleansing agents; (b) contacting an area of the skin affected by acne with the porous article such that the skin is contacted by the composition; and (c) removing the composition from the skin wherein residual benzoyl peroxide remains on the skin in an anti-acne effective amount. There are also anti-acne compositions. | 04-05-2012 |
20120046576 | Mid-face aesthetic scale and related methods - This disclosure relates to mid-face aesthetic scales and related methods for evaluating fullness in a mid-face area of a human patient's face. In exemplary embodiments, the mid-face area is defined as medial to the maxillary prominence, lateral to the medial canthus, inferior to the maxillary prominence, superior to the plane of nasal alae, and lateral to the nose. An exemplary method for evaluating fullness in a mid-face area of a human patient's face comprises visually comparing a plurality of views of the patient's mid-face against a mid-face scale, and assigning a grade from the scale to the patient's mid-face based on the visual comparison. | 02-23-2012 |
20110223261 | STABLE CLEANSER COMPOSITIONS CONTAINING SULFUR - The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders. | 09-15-2011 |
20100330131 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 12-30-2010 |
20090041846 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 02-12-2009 |
20080242642 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
20080242641 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
20080241241 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
20080241236 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
20080241235 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
20080241197 | MINOCYCLINE DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |